University of Texas MD Anderson Cancer Center scholar Ernest T. Hawk, MD has been recognized by the American Society for Clinical Oncology (ASCO) with the 2015 American Cancer Society Award tor his work in cancer prevention and control. Hawk was given the award at the 2015 ASCO Annual Meeting.
Ernest Hawk is the vice president and the head of Cancer Prevention and Population Sciences at MD Anderson Cancer Center, as well as the executive director of the Duncan Family Institute for Cancer Prevention and Risk Assessment, co-leader of the cancer prevention and control platform for MD Anderson’s Moon Shots Program, and holder of the Boone Pickens Distinguished Chair for Early Prevention of Cancer.
Due to his success in multiple roles and record of career accomplishments, ASCO has awarded Hawk the 2015 American Cancer Society Award. The researcher wants to help accelerate cancer prevention and control through his research, as well as support public policy, public and professional education, and implement and expand services within communities.
The ASCO Special Awards are given by the society to honor investigators, patient advocates and leaders in the oncology field for their dedication and contribution towards cancer prevention and treatment, while improving patient care. The ASCO-American Cancer Society Award is granted every year since 1993 and intends to recognize individual accomplishments.
“I am immensely honored and humbled to receive the ASCO-American Cancer Society award,” stated Hawk in a university press release. “The highlights of my career in cancer prevention have been the many incredible mentors, friends, students and teams from diverse disciplines, experiences and backgrounds that I’ve been privileged to work with along the way.”
“This award is accepted in recognition of the progress forged by those teams, and of all the patients, families and study participants who made it possible. The future of our field is exciting and exceptionally bright because of these people and their enduring commitment to advancing the best ideas in cancer prevention through scientific discovery, purpose-driven translation and trans-disciplinary collaboration,” he added.
With a bachelor and medical degree from Wayne State University and a master of public health from Johns Hopkins University, Hawk has dedicated his career to studying chemoprevention, such as nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and preventive agent combinations in high-risk cohorts. After earning an internal medicine internship and residency at Emory University, he completed a medical oncology clinical fellowship at the University of California, San Francisco and a cancer prevention fellowship at the National Cancer Institute (NCI), he joined MD Anderson in 2007.
At the cancer center, Hawk served in numerous positions, such as NCI chief and medical officer at the Gastrointestinal and Other Cancers Research Group, medical officer at the Chemoprevention Branch and chair of the Translational Research Working Group. Most recently, Hawk has worked on improving minorities and undeserved populations’ participation in clinical research.
Hawk had already been given several awards, such as the NCI Research Award for Distinguished Achievement in Cancer Prevention and the Distinguished Alumnus Award. This time, he was among other peers recognized in the oncology field, including researcher Jim Allison, PhD, also from the MD Anderson Cancer Center who was attributed the Science of Oncology Award for his scientific achievements leading to the discovery of novel cancer therapies.